Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking. The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).
Once the strip is placed under the lip and onto the gum, it delivers a quick and potent nicotine effect. Within a couple of minutes the nicotine has been expended and the product dissolves without leaving any residue in your mouth.
The product platform is formulated in Sweden and is the result of over ten years of research and development.
The product is a leaf thin and alginate based strip about half the size of a stamp. Each strip contains 1 mg of medically classified nicotine, an alginate base (extracted from brown seaweed), as well as natural flavorings and aromas. All additional substances are medically approved.
NICOTINE AND ITS HEALTH EFFECTS
Nicotine is a stimulant that has a relaxing effect. The Company is aware that the use of nicotine raises relevant questions about nicotine addiction and the effects that nicotine may have on certain demographic groups, such as pregnant women or patients suffering from cardiovascular diseases, as well as other groups that are advised to avoid nicotine for medical reasons. The product will be aimed at adult consumers who want to quit smoking.
APPROVAL AND LEGAL ASPECTS
Nicoccino™ is sold online through the Company’s website purenicoccino.com. The product adheres to the established General Safety Rules as a consumer product. After completion of the clinical study, the product will adhere to the regulations of the Medical Products Agency.